Protein and peptide biomarkers of myocardial ischemia
This project will identify novel biomarkers (diagnostics) of ischemia / reperfusion injury in the heart.
Cardiovascular disease (CVD) results in approximately 7 million deaths per annum world-wide and is the most significant cause of death in Australians. Many of these result from sequelae following myocardial ischemia / reperfusion (I/R) injury. Reduction or cessation of blood flow (ischemia) generally results from the formation of atherosclerotic lesions in the coronary arteries. Reintroduction of blood-flow (reperfusion) by thrombolysis or primary percutaneous coronary artery intervention remains the best strategy for resolving ischemia and preventing cell death and permanent cardiac dysfunction (infarction). Morbidity and mortality from acute myocardial infarction (AMI) remain significant. The endogenous or ‘native’ peptidome is the full complement of natural, low molecular mass (<10kDa) peptides, as well as those created by the proteolysis of larger proteins, contained within a cell, tissue or body fluid. Pathology is often underpinned by protein damage, particularly following protease activation. The peptidome is therefore a rich source of putative disease biomarkers. This project will utilize chromatography coupled with mass spectrometry to identify peptide biomarkers of I/R injury in animal models and thus act as a model for developing new and more effective strategy for the rapid diagnosis of myocardial ischemia.
Want to find out more?
The opportunity ID for this research opportunity is: 61
Other opportunities with Dr Stuart Cordwell